For additional evidence of the role of CCR5 in M2-mediated MM cell protection, we evaluated RPMI 8226 cell apoptosis after incubation with M2 macrophages treated Bortezomib in the presence or absence of MVC. This evidence concerns the gene CCR5 and Miyoshi myopathy.